GRIFOLS ADR 1/2/EO-50 Total Assets
GRIFOLS ADR 1/2/EO-50 total assets. Based on the latest financial reports, GRIFOLS ADR 1/2/EO-50 (G0F) holds total assets worth €19.71 Billion EUR (≈ $23.05 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see G0F stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of GRIFOLS ADR 1/2/EO-50 (2021–2025)
Total assets of GRIFOLS ADR 1/2/EO-50 from 2021 to 2025. This chart illustrates how GRIFOLS ADR 1/2/EO-50's total assets have evolved over time, based on quarterly financial data. See GRIFOLS ADR 1/2/EO-50 stock price for real-time trading data and today's change.
GRIFOLS ADR 1/2/EO-50 - Asset Composition Analysis
GRIFOLS ADR 1/2/EO-50 Total Assets Breakdown (December 2025)
GRIFOLS ADR 1/2/EO-50 total assets breakdown as of December 2025. GRIFOLS ADR 1/2/EO-50's total assets of €19.71 Billion consist of 25.7% current assets and 74.3% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 4.1% |
| Accounts Receivable | €651.00 Million | 3.3% |
| Inventory | €3.30 Billion | 16.7% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €2.73 Billion | 13.8% |
| Goodwill | €6.83 Billion | 34.7% |
Asset Composition Trend (2021–2025)
This chart illustrates how GRIFOLS ADR 1/2/EO-50's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore GRIFOLS ADR 1/2/EO-50 (G0F) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GRIFOLS ADR 1/2/EO-50's current assets represent 25.7% of total assets in 2025, a decrease from 28.7% in 2021.
- Cash Position: Cash and equivalents constituted 4.1% of total assets in 2025, up from 3.4% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 47.0% of total assets, an increase from 40.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 34.7% of total assets.
GRIFOLS ADR 1/2/EO-50 Competitors by Total Assets
Key competitors of GRIFOLS ADR 1/2/EO-50 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Novartis AG
SW:NOVN
|
Switzerland | CHF118.89 Billion |
|
Virbac SA
PA:VIRP
|
France | €1.82 Billion |
|
AstraZeneca PLC
LSE:AZN
|
UK | GBX116.43 Billion |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771
|
China | CN¥2.55 Billion |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.18 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$2.28 Million |
|
Eli Lilly and Company
SA:LILY34
|
Brazil | R$116.58 Billion |
GRIFOLS ADR 1/2/EO-50 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.51 | 2.66 | 1.68 |
| Quick Ratio | 0.88 | 1.01 | 0.80 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €3.06 Billion | €3.57 Billion | €2.80 Billion |
GRIFOLS ADR 1/2/EO-50 - Advanced Valuation Insights
This section examines the relationship between GRIFOLS ADR 1/2/EO-50's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.12 |
| Latest Market Cap to Assets Ratio | 0.21 |
| Asset Growth Rate (YoY) | -7.9% |
| Total Assets | €19.71 Billion |
| Market Capitalization | $4.21 Billion USD |
Valuation Analysis
Below Book Valuation: The market values GRIFOLS ADR 1/2/EO-50's assets below their book value (0.21x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: GRIFOLS ADR 1/2/EO-50's assets decreased by 7.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for GRIFOLS ADR 1/2/EO-50 (2021–2025)
The table below shows the annual total assets of GRIFOLS ADR 1/2/EO-50 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €19.71 Billion ≈ $23.05 Billion |
-7.91% |
| 2024-12-31 | €21.41 Billion ≈ $25.02 Billion |
+1.97% |
| 2023-12-31 | €20.99 Billion ≈ $24.54 Billion |
-1.12% |
| 2022-12-31 | €21.23 Billion ≈ $24.82 Billion |
+10.38% |
| 2021-12-31 | €19.23 Billion ≈ $22.49 Billion |
-- |
About GRIFOLS ADR 1/2/EO-50
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, u… Read more